Yousif Capital Management LLC Has $584,000 Stock Holdings in Integra LifeSciences Holdings Co. (NASDAQ:IART)

Yousif Capital Management LLC lessened its stake in Integra LifeSciences Holdings Co. (NASDAQ:IART) by 3.4% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 25,762 shares of the life sciences company’s stock after selling 906 shares during the quarter. Yousif Capital Management LLC’s holdings in Integra LifeSciences were worth $584,000 at the end of the most recent reporting period.

Several other hedge funds also recently modified their holdings of IART. KBC Group NV increased its stake in shares of Integra LifeSciences by 65.2% during the 3rd quarter. KBC Group NV now owns 2,839 shares of the life sciences company’s stock worth $52,000 after purchasing an additional 1,120 shares during the last quarter. Northwest Investment Counselors LLC acquired a new position in shares of Integra LifeSciences during the 3rd quarter worth $73,000. Nisa Investment Advisors LLC increased its stake in shares of Integra LifeSciences by 599.6% during the 4th quarter. Nisa Investment Advisors LLC now owns 3,267 shares of the life sciences company’s stock worth $74,000 after purchasing an additional 2,800 shares during the last quarter. Centiva Capital LP acquired a new position in shares of Integra LifeSciences during the 3rd quarter worth $192,000. Finally, Dynamic Technology Lab Private Ltd acquired a new position in shares of Integra LifeSciences during the 3rd quarter worth $198,000. Institutional investors and hedge funds own 84.78% of the company’s stock.

Integra LifeSciences Trading Down 0.3 %

IART opened at $24.18 on Monday. The company has a current ratio of 1.20, a quick ratio of 0.73 and a debt-to-equity ratio of 0.79. The stock has a market capitalization of $1.87 billion, a PE ratio of -268.64, a PEG ratio of 0.87 and a beta of 1.17. Integra LifeSciences Holdings Co. has a 1-year low of $16.81 and a 1-year high of $45.42. The firm has a 50-day moving average price of $23.86 and a two-hundred day moving average price of $21.82.

Analyst Upgrades and Downgrades

Several research analysts have recently commented on IART shares. Morgan Stanley started coverage on shares of Integra LifeSciences in a research note on Monday, December 2nd. They set an “underweight” rating and a $20.00 price target on the stock. Citigroup increased their price target on shares of Integra LifeSciences from $16.00 to $22.00 and gave the stock a “sell” rating in a research note on Tuesday, November 5th. Three investment analysts have rated the stock with a sell rating, five have issued a hold rating and one has assigned a buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $23.00.

Insider Buying and Selling

In related news, EVP Michael J. Mcbreen sold 1,700 shares of Integra LifeSciences stock in a transaction that occurred on Monday, December 2nd. The shares were sold at an average price of $24.16, for a total transaction of $41,072.00. Following the transaction, the executive vice president now owns 56,182 shares of the company’s stock, valued at $1,357,357.12. This trade represents a 2.94 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. 3.10% of the stock is owned by insiders.

About Integra LifeSciences

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.